EVGN — Evogene Ltd.
Evogene Ltd., along with its subsidiaries, operates as a computational biology firm. Its core activity involves the discovery and advancement of products across diverse life-science sectors, such as human health and agriculture, primarily leveraging its proprietary Computational Predictive Biology (CPB) platform. This platform, built on deep biological insights, big data analytics, and artificial intelligence, is engineered to digitally identify and strategically guide the creation of life-science solutions derived from microbes, small molecules, and genetic components. The company's operations are structured into three primary divisions: Agriculture, Human Health, and Industrial Applications. Within the Agriculture division, Evogene works on seed traits, agricultural chemicals, and biological products aimed at improving plant yields, with efforts spanning critical crops like corn, soybean, wheat, rice, and cotton. The Industrial Applications segment focuses on enhancing castor bean seeds for use as a raw material in various industrial applications. Meanwhile, the Human Health segment is dedicated to uncovering and developing human microbiome-based treatments for conditions including immuno-oncology, gastrointestinal disorders, and antimicrobial-resistant infections. Beyond these core areas, Evogene also delivers medical cannabis products. The company maintains a global presence, conducting operations in the United States, Israel, Brazil, and other international markets. It has forged key partnerships and licensing agreements with leading agricultural enterprises, such as BASF SE, Corteva, and Bayer. Additionally, its subsidiary, Canonic Ltd., collaborates with Cannbit Ltd. on the development of innovative medical cannabis offerings. Established in 1999, Evogene Ltd. is based in Rehovot, Israel.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: IL
- Exchange: NASDAQ Global Market
- Employees: 117
- Website: https://www.evogene.com
Latest SEC filings for EVGN
- 6-K — 2026-10-06
- 6-K — 2026-09-30
- EFFECT — 2026-09-30
- POS AM — 2026-09-28
- 6-K — 2026-09-28
- 6-K — 2026-09-15
- SCHEDULE 13D/A — 2026-09-11
- 6-K — 2026-09-04
- 6-K — 2026-08-27
- 6-K — 2026-08-18
Latest EVGN news
- — Evogene and Pure Capital Group Reach Cooperation Agreement to Resolve Differences and Reconstitute Board of Directors (prnewswire.com)
- — Evogene reports Nasdaq grants additional 180-day period to regain minimum bid price compliance (seekingalpha_market)
- — Evogene Reports Nasdaq Grants Additional 180-Day Period to Regain Minimum Bid Price Compliance (prnewswire.com)
- — Evogene Updates SEC Filings With Weakening Mid-2026 Balance Sheet - TipRanks (TipRanks)
- — Evogene GAAP EPS of -$0.63, revenue of $0.68M (seekingalpha_market)
- — After about $2M in seed sales a year earlier, first-half revenue fell at Evogene (EVGN). - Stock Titan (Stock Titan)
- — All 3,384,616 shares were sold; Evogene (EVGN) moves to end their resale registration. - Stock Titan (Stock Titan)
- — Evogene Stock Price Forecast. Should You Buy EVGN? - StockInvest.us (StockInvest.us)
Educational tool only — not investment advice.